Business, energy, technology, markets and global industry news from Business News Today

Amgen Inc.

PharmaDeviceNews Amgen Inc.
Representative biotech patent litigation image showing antibody discovery research, laboratory documents and legal symbols.
Pharma & Biotech

Could Harbour BioMed’s legal win reshape the economics of antibody drug discovery?

Read how Harbour BioMed’s Amgen patent win could reshape antibody discovery licensing, biologics IP and biotech investor sentiment.

Read More
Representative image of autoimmune disease drug safety review as Amgen’s Tavneos scrutiny puts ANCA vasculitis treatment, FDA approval standards, liver risk, and rare disease evidence under sharper focus.
Pharma & Biotech

Amgen turns to Duke as FDA scrutiny puts Tavneos rare autoimmune disease role at risk

Find out how Amgen’s Tavneos data review could shape FDA withdrawal risk, liver safety scrutiny, and ANCA vasculitis care.

Read More
Representative image: An oncologist reviews lung scan images in a modern cancer care setting, reflecting Amgen’s EU approval for Imdylltra in relapsed extensive-stage small cell lung cancer.
Pharma & Biotech

Why Amgen’s Imdylltra EU approval could reshape second-line small cell lung cancer treatment

Find out how Amgen’s Imdylltra EU approval could change relapsed small cell lung cancer treatment across Europe.

Read More
Pharma & Biotech

Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight

FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.

Read More